Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).
Amanda Psyrri(National and Kapodistrian University of Athens), Periklis Foukas(National and Kapodistrian University of Athens), Niki Gavrielatou(National and Kapodistrian University of Athens), Sylvie Rusakiewicz(Inserm), George Coukos(Ludwig Cancer Research), Evgenia Kousidou(University General Hospital Attikon), Ekaterina Fortis(Centre Hospitalier Universitaire Vaudois), Μaria Anastasiou(National and Kapodistrian University of Athens), Aris Spathis(National and Kapodistrian University of Athens), Μαρία Γκοτζαμανίδου(National and Kapodistrian University of Athens), Ioannis Kotsantis(National and Kapodistrian University of Athens), Elena Vagia(Northwestern University), Panagiota Economopoulou(National and Kapodistrian University of Athens), Athina Kladi-Skandali(National and Kapodistrian University of Athens), Ioannis G. Panayiotides(National and Kapodistrian University of Athens)
Cited by 2
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Consensus guidelines for the use and interpretation of angiogenesis assays
|Angiogenesis|2018|602
Deciphering and Reversing Tumor Immune Suppression
|Immunity|2013|597